Skip to content

Public FDA record

Z-1358-2023: Agilent Resolution ctDx FIRST Sample Collection Kit, 500032

Recall record Z-1358-2023 for AGILENT TECHNOLOGIES INC./US. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1358-2023
Company in FDA record
AGILENT TECHNOLOGIES INC./US
FDA classification date
Apr 11, 2023
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class III

Reason stated in the source

Distributed sample collection kit with an unapproved instruction for use.

Source facts

Action
On 02/17/2023, the firm verbally notified its customers that as part of their post-approval commitments to FDA, a final version of the product labeling was submitted to FDA on 01/17/2023. Upon FDA's review of the final label version, FDA deemed the Instruction For Use changes to be significant, such as, changes to allow use of an alternate form to document patient information and modified shipping instructions. On or about 03/23/2023, a formal updated "URGENT: Medical Device Recall" letter will be communicated to customer providing them with the recall details. Customers are instructed to: 1. Stop use of Sample Collection Kits and place under quarantine (see Table 1 for affected product and lot numbers). 2. Complete the following four (4) records and return them to Resolution s Quality Team at qa.pdl-resolution@agilent.com: i. Attachment 1, Recall Acknowledgement and Customer Return Form: Confirm that you have received this notification by returning enclosed acknowledgement form within 3 business days of receipt, answering the questions, documenting the inventory quantities, and completing the acknowledgement box. ii. Prepare the inventory for return according to provided instructions in Attachment 2, Shipping Instructions iii. Attachment 3, Product Return - Shipping Record: For each lot number and Quest Hub location, record the number of unused products being returned, shipped by and date, shipping tracking number, scan attachment 3 and email to qa.pdl-resolution@agilent.com, include attachment 3 with the shipment. iv. Attachment 4, Certification of Product Destruction Record: If there are any devices that were opened or in the process of being used please document their destruction in this attachment, scan and return via email to qa.pdl-resolution@agilent.com. Destroy devices following your laboratory procedures as deemed appropriate by your company. For questions, contact Agilent Corporate Communications at 669-225-7696 or via emails at sarah.litton@agilent.co
Initiated
2023-02-17
Root cause
Labeling Change Control
Distribution
U.S. Nationwide distribution in the states of CA, GA, IN, NJ, and TX. O.U.S.: None
Recall number
Z-1358-2023
Recall status
Open, Classified
CDRH record ID
199072
FDA classified
2023-04-11
Recall event number
91863

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗